(redirected from Tamoxifen citrate)
Also found in: Thesaurus, Medical, Encyclopedia.


(ˈnoʊl vəˌdɛks) Trademark.
a brand of tamoxifen.
Random House Kernerman Webster's College Dictionary, © 2010 K Dictionaries Ltd. Copyright 2005, 1997, 1991 by Random House, Inc. All rights reserved.
References in periodicals archive ?
They have concluded that the Tamoxifen citrate reduces the level of sperm chromatin condensation by decreasing testicular levels of TP1, TP2, protamine 1 and response element modulator-[tau] (CREMs) proteins, which are effective in chromatin compaction in the spermatogenesis process, and also TX can affect the expression of these genes in both levels of transcription and post-translational modifications (34).
Long-term tamoxifen citrate use and potential ocular toxicity.
Mukherjee, "Development of biodegradable polymer based tamoxifen citrate loaded nanoparticles and effect of some manufacturing process parameters on them: a physicochemical and in-vitro evaluation," International Journal of Nanomedicine, vol.
DARA holds exclusive US marketing rights to Gelclair oral rinse gel, Oravig (miconazole) buccal tablets and Soltamox (tamoxifen citrate oral liquid solution).
(24.) See, e.g., In re Tamoxifen Citrate Antitrust Litig., 466 F.3d 187 (2d Cir.
In the April ruling that upheld the $400 million payment to Barr, the 2nd Circuit relied on the precedent it set with its 2006 decision In re Tamoxifen Citrate Antitrust Litigation.
has announced that SOLTAMOX(tm) (tamoxifen citrate, oral solution 10mg/5mL), the first liquid form of the hormonal breast cancer therapy tamoxifen, is currently being introduced in the United States and is available in U.S.
(Woodcliff Lake, NJ) announced that the United States Court of Appeals for the Second Circuit has denied the plaintiffs' petitions for rehearing and rehearing en banc in the Tamoxifen Citrate antitrust lawsuits.
The drug tamoxifen citrate not only helps prevent recurrence of breast cancer, but can keep the deadly disease from appearing in the first place in some women.
Since the beginning of 2003 Teva USA has introduced 24 new products to the market, among them Tamoxifen Citrate tablets, AB rated and bioequivalent to AstraZeneca PLC's Nolvadex; Budprion SR and Buproban (Bupropion HCI extended-release tablets), AB rated and bioequivalent to GlaxoSmithKline PLC's Wellbutrin SR and Zyban, respectively; and Oxycodone HCI extended-release tablets, AB rated and bioequivalent to Purdue Pharma LP's OxyContin.